Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma

• Verfasst von: Miller, Suzanne [VerfasserIn]
• Verfasst von: Rogers, Hazel A. [VerfasserIn]
• Verfasst von: Lyon, Paul [VerfasserIn]
• Verfasst von: Rand, Vikki [VerfasserIn]
• Verfasst von: Adamowicz-Brice, Martyna [VerfasserIn]
• Verfasst von: Clifford, Steven C. [VerfasserIn]
• Verfasst von: Hayden, James T. [VerfasserIn]
• Verfasst von: Dyer, Sara [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Verfasst von: Korshunov, Andrey [VerfasserIn]
• Verfasst von: Brundler, Marie-Anne [VerfasserIn]
• Verfasst von: Lowe, James [VerfasserIn]
• Verfasst von: Coyle, Beth [VerfasserIn]
• Verfasst von: Grundy, Richard G. [VerfasserIn]
• Titel: Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma
• Verf.angabe: Suzanne Miller, Hazel A. Rogers, Paul Lyon, Vikki Rand, Martyna Adamowicz-Brice, Steven C. Clifford, James T. Hayden, Sara Dyer, Stefan Pfister, Andrey Korshunov, Marie-Anne Brundler, James Lowe, Beth Coyle, and Richard G. Grundy
• E-Jahr: 2011
• Jahr: 20 July 2011
• Umfang: 14 S.
• Fussnoten: Gesehen am 19.08.2022
• Titel Quelle: Enthalten in: Neuro-Oncology
• Ort Quelle: Oxford : Oxford Univ. Press, 1999
• Jahr Quelle: 2011
• Band/Heft Quelle: 13(2011), 8, Seite 866-879
• ISSN Quelle: 1523-5866
• DOI: doi:10.1093/neuonc/nor070
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1814752501

Abstract

Central nervous system primitive neuroectodermal tumor (CNS PNET) and pineoblastoma are highly malignant embryonal brain tumors with poor prognoses. Current therapies are based on the treatment of pediatric medulloblastoma, even though these tumors are distinct at both the anatomical and molecular level. CNS PNET and pineoblastoma have a worse clinical outcome than medulloblastoma; thus, improved therapies based on an understanding of the underlying biology of CNS PNET and pineoblastoma are needed. To this end, we characterized the genomic alterations of 36 pediatric CNS PNETs and 8 pineoblastomas using Affymetrix single nucleotide polymorphism arrays. Overall, the majority of CNS PNETs contained a greater degree of genomic imbalance than pineoblastomas, with gain of 19p (8 [27.6%] of 29), 2p (7 [24.1%] of 29), and 1q (6 [20.7%] of 29) common events in primary CNS PNETs. Novel gene copy number alterations were identified and corroborated by Genomic Identification of Significant Targets In Cancer (GISTIC) analysis: gain of PCDHGA3, 5q31.3 in 62.1% of primary CNS PNETs and all primary pineoblastomas and FAM129A, 1q25 in 55.2% of primary CNS PNETs and 50% of primary pineoblastomas. Comparison of our GISTIC data with publically available data for medulloblastoma confirmed these CNS PNET-specific copy number alterations. With use of the collection of 5 primary and recurrent CNS PNET pairs, we found that gain of 2p21 was maintained at relapse in 80% of cases. Novel gene copy number losses included OR4C12, 11p11.12 in 48.2% of primary CNS PNETs and 50% of primary pineoblastomas. Loss of CDKN2A/B (9p21.3) was identified in 14% of primary CNS PNETs and was significantly associated with older age among children (P = .05). CADPS, 3p14.2 was lost in 27.6% of primary CNS PNETs and was associated with poor prognosis (P = .043). This genome-wide analysis revealed the marked molecular heterogeneity of CNS PNETs and enabled the identification of novel genes and clinical associations potentially involved in the pathogenesis of these tumors.